Mallinckrodt Plc

Mallinckrodt Plc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)21.82
  • Today's Change0.21 / 0.97%
  • Shares traded1.71m
  • 1 Year change-51.07%
  • Beta1.2910
Data delayed at least 15 minutes, as of Jul 18 2018 21:02 BST.
More ▼

Profile data is unavailable for this security.

About the company

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

  • Revenue in USD (TTM)2.98bn
  • Net income in USD1.24bn
  • Incorporated2013
  • Employees3.90k
  • Location
    Mallinckrodt Plc3 Lotus Park, The CausewaySTAINES TW18 3AGUnited KingdomGBR
  • Phone+44 17 8463 6700
  • Websitehttp://mallinckrodt.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MNK:NYQ since
Sucampo Pharmaceuticals IncDeal completed26 Dec 201726 Dec 2017Deal completed-6.43%882.22m
Ocera Therapeutics IncDeal completed02 Nov 201702 Nov 2017Deal completed-31.94%108.71m
InfaCare Pharmaceutical CorpDeal completed04 Aug 201704 Aug 2017Deal completed-47.57%425.00m
Data delayed at least 15 minutes, as of Jul 18 2018 21:02 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Achillion Pharmaceuticals, Inc.0.00-85.67m408.10m88.00--1.33-----0.6231-0.62310.002.220.00----0.00-24.17-19.89-24.83-20.81-------345.07----0.0008---100.00---38.13---0.9318--
DSwiss Inc182.58k-291.02k451.05m7.00--928.42--2,470.44-0.0014-0.00140.00090.00240.25370.664114.3026,082.86-40.43---46.76--80.31---159.39--6.63--0.0297--32.24--44.79------
Mallinckrodt PLC2.98bn1.24bn1.80bn3.90k1.620.280.87590.601813.3418.5131.9077.160.1975.137.39764,948.708.20--8.82--50.77--41.65--1.901.200.5133--------------
TRHF Company Ltd Inc82.14k-442.14k1.80bn--------21,913.81-0.0007-0.00070.00010.50780.000310.2953.17---0.175---0.1752--62.47---538.28--0.0079--0.3963--6.82---93.99------
Diplomat Pharmacy Inc4.75bn2.87m1.92bn2.18k604.912.5424.670.40420.04280.155167.6710.183.2522.1516.232,181,431.000.18410.95070.27361.667.887.290.05660.22250.56760.97980.44170.001.7031.82-72.83--18.65--
Heron Therapeutics Inc38.70m-199.42m2.74bn145.00--29.73--70.83-3.46-3.460.67221.280.20760.54331.61266,910.30-106.94-119.24-163.21-161.9883.11---515.27-1,871.901.72-106.160.2386--2,305.55---14.06--21.30--
Data as of Jul 18 2018. Currency figures normalised to Mallinckrodt Plc's reporting currency: US Dollar USD

Institutional shareholders

62.38%Per cent of shares held by top holders
HolderShares% Held
Scopia Capital Management LPas of 31 Mar 20188.63m10.38%
Deerfield Management Company LPas of 09 May 20188.31m10.00%
The Vanguard Group, Inc.as of 31 Mar 20188.05m9.69%
BlackRock Fund Advisorsas of 31 Mar 20187.59m9.13%
Dimensional Fund Advisors LPas of 31 Mar 20184.08m4.91%
Paulson & Co., Inc.as of 31 Mar 20183.67m4.42%
SSgA Funds Management, Inc.as of 31 Mar 20183.64m4.39%
Hotchkis & Wiley Capital Management LLCas of 31 Mar 20182.70m3.25%
LSV Asset Managementas of 31 Mar 20182.63m3.16%
AllianceBernstein LPas of 31 Mar 20182.53m3.05%
More ▼
Data from 31 Mar 2018 - 31 Mar 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.